Unique fusion is associated with marked response to crizotinib in lung adenocarcinoma

Unique fusion is associated with marked response to crizotinib in lung adenocarcinoma

Chromosomal rearrangements involving the c-ros oncogene 1 ( ROS1 ) gene define a subset of non-small cell lung cancers highly sensitive to small-molecule tyrosine kinase inhibitors. However, little is known about the impact of different fusion partners on tyrosine kinase inhibitor efficacy. We herei...

Full description

Bibliographic Details
Main Authors: Maurício Fernando Silva Almeida Ribeiro, Luiza Lara Gadotti, Karina Perez Sacardo, Carlos Diego Holanda Lopes, Rodrigo Saddi, João Victor Machado Alessi, Mariana Petaccia de Macedo, Ellen Caroline Toledo do Nascimento, Leonardo de Abreu Testagrossa, Artur Katz
Format: Article
Language:English
Published: SAGE Publishing 2022-05-01
Series:SAGE Open Medical Case Reports
Online Access:https://doi.org/10.1177/2050313X221100407

Internet

https://doi.org/10.1177/2050313X221100407

Similar Items